{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:14:25Z","timestamp":1789017265986,"version":"build-2803163510"},"reference-count":44,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2023,5,1]]},"abstract":"<jats:sec id=\"ab-hoi230009-4\"><jats:title>Importance<\/jats:title><jats:p>Anthracycline-containing regimens are highly effective for diffuse large B-cell lymphoma (DLBCL); however, patients with preexisting heart failure (HF) may be less likely to receive anthracyclines and may be at higher risk of lymphoma mortality.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi230009-5\"><jats:title>Objective<\/jats:title><jats:p>To assess the prevalence of preexisting HF in older patients with DLBCL and its association with treatment patterns and outcomes.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi230009-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This longitudinal cohort study used data from the Surveillance, Epidemiology, and End Results (SEER)\u2013Medicare registry from 1999 to 2016. The SEER registry is a system of population-based cancer registries, capturing more than 25% of the US population. Linkage to Medicare offers additional information from billing claims. This study included individuals 65 years and older with newly diagnosed DLBCL from 2000 to 2015 with Medicare Part A or B continuously in the year prior to lymphoma diagnosis. Data were analyzed from September 2020 to December 2022.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi230009-7\"><jats:title>Exposures<\/jats:title><jats:p>Preexisting HF in the year prior to DLBCL diagnosis ascertained from billing codes required one of the following: (1) 1 primary inpatient discharge diagnosis, (2) 2 outpatient diagnoses, (3) 3 secondary inpatient discharge diagnoses, (4) 3 emergency department diagnoses, or (5) 2 secondary inpatient discharge diagnoses plus 1 outpatient diagnosis.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi230009-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary outcome was anthracycline-based treatment. The secondary outcomes were (1) cardioprotective medications and (2) cause-specific mortality. The associations between preexisting HF and cancer treatment were estimated using multivariable logistic regression. The associations between preexisting HF and cause-specific mortality were evaluated using cause-specific Cox proportional hazards models with adjustment for comorbidities and cancer treatment.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi230009-9\"><jats:title>Results<\/jats:title><jats:p>Of 30\u202f728 included patients with DLBCL, 15 474 (50.4%) were female, and the mean (SD) age was 77.8 (7.2) years. Preexisting HF at lymphoma diagnosis was present in 4266 patients (13.9%). Patients with preexisting HF were less likely to be treated with an anthracycline (odds ratio, 0.55; 95% CI, 0.49-0.61). Among patients with preexisting HF who received an anthracycline, dexrazoxane or liposomal doxorubicin were used in 78 of 1119 patients (7.0%). One-year lymphoma mortality was 41.8% (95% CI, 40.5-43.2) with preexisting HF and 29.6% (95% CI, 29.0%-30.1%) without preexisting HF. Preexisting HF was associated with higher lymphoma mortality in models adjusting for baseline and time-varying treatment factors (hazard ratio, 1.24; 95% CI, 1.18-1.31).<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi230009-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this study, preexisting HF in patients with newly diagnosed DLBCL was common and was associated with lower use of anthracyclines and lower use of any chemotherapy. Trials are needed for this high-risk population.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamacardio.2023.0303","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T16:51:15Z","timestamp":1680108675000},"page":"453","source":"Crossref","is-referenced-by-count":21,"title":["Association of Preexisting Heart Failure With Outcomes in Older Patients With Diffuse Large B-Cell Lymphoma"],"prefix":"10.1001","volume":"8","author":[{"given":"Jenica N.","family":"Upshaw","sequence":"first","affiliation":[{"name":"Division of Cardiology, Tufts Medical Center, Boston, Massachusetts"},{"name":"Institute of Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Nelson","sequence":"additional","affiliation":[{"name":"Institute of Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angie Mae","family":"Rodday","sequence":"additional","affiliation":[{"name":"Institute of Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita J.","family":"Kumar","sequence":"additional","affiliation":[{"name":"Institute of Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts"},{"name":"Division of Hematology-Oncology, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas K.","family":"Klein","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin A.","family":"Konstam","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Wong","sequence":"additional","affiliation":[{"name":"Institute of Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris Z.","family":"Jaffe","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Tufts Medical Center, Boston, Massachusetts"},{"name":"Molecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Ky","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[{"name":"Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Maurer","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Kent","sequence":"additional","affiliation":[{"name":"Institute of Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan K.","family":"Parsons","sequence":"additional","affiliation":[{"name":"Institute of Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts"},{"name":"Division of Hematology-Oncology, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"11","key":"hoi230009r2","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity.","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat Med"},{"issue":"22","key":"hoi230009r3","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"issue":"34","key":"hoi230009r4","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1200\/JCO.2017.72.4211","article-title":"Preexisting cardiovascular risk and subsequent heart failure among non-Hodgkin lymphoma survivors.","volume":"35","author":"Salz","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"hoi230009r5","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1200\/JCO.2015.64.0409","article-title":"Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study.","volume":"34","author":"Armenian","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"hoi230009r6","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.clbc.2019.04.012","article-title":"Personalized decision making in early stage breast cancer: applying clinical prediction models for anthracycline cardiotoxicity and breast cancer mortality demonstrates substantial heterogeneity of benefit-harm trade-off.","volume":"19","author":"Upshaw","year":"2019","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"hoi230009r7","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000472","article-title":"Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.","volume":"3","author":"Ezaz","year":"2014","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"hoi230009r8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.v72.1","article-title":"Cancer statistics, 2022.","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"hoi230009r9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1200\/JCO.1998.16.1.86","article-title":"Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas.","volume":"16","author":"Lopez","year":"1998","journal-title":"J Clin Oncol"},{"issue":"3","key":"hoi230009r10","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.","volume":"15","author":"O\u2019Brien","year":"2004","journal-title":"Ann Oncol"},{"key":"hoi230009r11","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ejca.2016.02.004","article-title":"Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: a randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikament\u00f6se Tumortherapie AGMT](NHL-14).","volume":"58","author":"Fridrik","year":"2016","journal-title":"Eur J Cancer"},{"issue":"23","key":"hoi230009r12","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","article-title":"Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (Prevention of Left Ventricular Dysfunction With Enalapril and Carvedilol in Patients Submitted to Intensive Chemotherapy for the Treatment of Malignant Hemopathies).","volume":"61","author":"Bosch","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"hoi230009r13","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"issue":"8","key":"hoi230009r14","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"issue":"17","key":"hoi230009r15","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1001\/jama.296.17.2105","article-title":"Statin therapy and risks for death and hospitalization in chronic heart failure.","volume":"296","author":"Go","year":"2006","journal-title":"JAMA"},{"issue":"6","key":"hoi230009r16","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1093\/aje\/kwx257","article-title":"External validation of the claims-based frailty index in the national health and aging trends study cohort.","volume":"186","author":"Segal","year":"2017","journal-title":"Am J Epidemiol"},{"issue":"2","key":"hoi230009r17","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/aje\/kwp107","article-title":"Competing risk regression models for epidemiologic data.","volume":"170","author":"Lau","year":"2009","journal-title":"Am J Epidemiol"},{"issue":"11","key":"hoi230009r18","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Tutorial in biostatistics: competing risks and multi-state models.","volume":"26","author":"Putter","year":"2007","journal-title":"Stat Med"},{"issue":"19","key":"hoi230009r19","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1200\/JCO.2007.14.1242","article-title":"Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin\u2019s lymphoma.","volume":"26","author":"Hershman","year":"2008","journal-title":"J Clin Oncol"},{"issue":"8","key":"hoi230009r20","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","article-title":"Heart disease and stroke statistics-2022 update: a report from the American Heart Association.","volume":"145","author":"Tsao","year":"2022","journal-title":"Circulation"},{"issue":"1","key":"hoi230009r21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jaccao.2022.01.100","article-title":"Incident cardiovascular disease among adults with cancer: a population-based cohort study.","volume":"4","author":"Paterson","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"3","key":"hoi230009r22","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/ejhf.2016.18.issue-3","article-title":"Incidence of cancer in patients with chronic heart failure: a long-term follow-up study.","volume":"18","author":"Banke","year":"2016","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"hoi230009r23","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jaccao.2021.11.007","article-title":"Cancer incidence and mortality according to pre-existing heart failure in a community-based cohort.","volume":"4","author":"Bertero","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"1","key":"hoi230009r24","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1200\/JCO.1992.10.1.117","article-title":"ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.","volume":"10","author":"Speyer","year":"1992","journal-title":"J Clin Oncol"},{"issue":"4","key":"hoi230009r25","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1200\/JCO.1997.15.4.1318","article-title":"Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.","volume":"15","author":"Swain","year":"1997","journal-title":"J Clin Oncol"},{"issue":"1","key":"hoi230009r27","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jaccao.2019.08.003","article-title":"Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer.","volume":"1","author":"Macedo","year":"2019","journal-title":"JACC CardioOncol"},{"key":"hoi230009r28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40959-019-0036-7","article-title":"Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series.","volume":"5","author":"Ganatra","year":"2019","journal-title":"Cardiooncology"},{"issue":"4","key":"hoi230009r30","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1200\/JCO.2013.49.7586","article-title":"De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial.","volume":"32","author":"Fields","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"hoi230009r31","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.1016\/S2352-3026(18)30054-1","article-title":"Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial.","volume":"5","author":"Shen","year":"2018","journal-title":"Lancet Haematol"},{"issue":"5","key":"hoi230009r32","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1182\/bloodadvances.2020002982","article-title":"Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines.","volume":"5","author":"Moccia","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"hoi230009r33","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol"},{"issue":"7","key":"hoi230009r34","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1161\/CIRCULATIONAHA.120.046471","article-title":"Early cardiac remodeling promotes tumor growth and metastasis.","volume":"142","author":"Avraham","year":"2020","journal-title":"Circulation"},{"key":"hoi230009r35","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.v23.3","article-title":"Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure.","author":"Bozkurt","journal-title":"J Card Fail"},{"issue":"5","key":"hoi230009r36","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.cardfail.2022.02.009","article-title":"2022 American College of Cardiology\/American Heart Association\/Heart Failure Society of America Guideline for the management of heart failure: executive summary.","volume":"28","author":"Heidenreich","year":"2022","journal-title":"J Card Fail"},{"issue":"3","key":"hoi230009r37","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1161\/CIR.0000000000001038","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"145","author":"Lawton","year":"2022","journal-title":"Circulation"},{"issue":"5","key":"hoi230009r38","first-page":"e72","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"issue":"10","key":"hoi230009r39","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.jacc.2019.03.009","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"hoi230009r40","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","article-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.","volume":"74","author":"January","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"hoi230009r41","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/j.jtcvs.2014.11.002","article-title":"2014 ACC\/AHA\/AATS\/PCNA\/SCAI\/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.","volume":"149","author":"Fihn","year":"2015","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"4","key":"hoi230009r42","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement.","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"issue":"11","key":"hoi230009r43","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.v22.11","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"hoi230009r44","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1200\/JOP.2016.018770","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline summary.","volume":"13","author":"Armenian","year":"2017","journal-title":"J Oncol Pract"},{"key":"hoi230009r1","unstructured":"National Comprehensive Cancer Network. B-cell lymphomas. Accessed May 10, 2022. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1480"},{"key":"hoi230009r26","unstructured":"Zinecard. Package insert. Pfizer; 2014. Accessed August 15, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/020212s017lbl.pdf"},{"key":"hoi230009r29","unstructured":"Doxil. Package insert. Baxter; 2007. Accessed August 15, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/050718s029lbl.pdf"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2803102\/jamacardiology_upshaw_2023_oi_230009_1683144885.02074.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T16:56:56Z","timestamp":1683737816000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2803102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2023.0303","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,1]]}}}